EGFR mutation testing and first line treatment of patients with advanced NSCLC and positive EGFR mutation status: results from a German registry.

Eberhardt, W., Thomas, M., Graf von der Schulenburg, J.-M., Dietel, M., Schirmacher, P., Gutendorf, P., Zirrgiebel, U., Schütte, W., 2011.

EMCC / ESMO, European Multidisciplinary Cancer Congress, Stockholm (Poster 133), 664.

Studie: REASON; Indikation: Bronchialkarzinom; Jahr: 2011; Veranstaltung: EMCC (ESMO); Journal: -

iOMEDICO AG
Hanferstraße 28
79108 Freiburg

Tel: 0761 - 15 242 0
E-Mail: info@iomedico.com